Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：10

作者：

Ayyappan, Sabarish ^{[1
]}

Kim, Won Seog ^{[2
]}

Kim, Tae Min ^{[3
]}

Walewski, Jan ^{[4
]}

Cho, Seok-Goo ^{[5
]}

Jarque, Isidro ^{[6
]}

Iskierka-Jazdzewska, Elzbieta ^{[7
]}

Poon, Michelle ^{[8
]}

Oh, Sung Yong ^{[9
]}

Lim, Francesca Lorraine Wei Inng ^{[10
]}

Carpio, Cecilia ^{[11
]}

Tan, Tran-Der ^{[12
]}

Gutierrez, Antonio ^{[13
]}

Zhang, Huilai ^{[14
]}

Cao, Junning ^{[15
]}

Zhang, Mingzhi ^{[16
,17
]}

Tessoulin, Benoit ^{[18
,19
]}

Li, Jingjin ^{[20
]}

Ufkin, Melanie ^{[20
]}

Shariff, Saleem ^{[21
]}

Chi, Lei ^{[20
]}

Chaudhry, Aafia ^{[20
]}

Mohamed, Hesham ^{[20
]}

Ambati, Srikanth ^{[20
]}

Prince, H. Miles ^{[22
,23
]}

机构：

[1] Univ Iowa Hosp & Clin, Iowa City, IA USA

[2] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[4] Marii Sklodowskiej Curie Panstwowy Inst Badawczy, Narodowy Inst Onkol, Warsaw, Poland

[5] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[6] Hosp Univ La Fe, Valencia, Spain

[7] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[8] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore

[9] Dong A Univ Hosp, Busan, South Korea

[10] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[11] Autonomous Univ Barcelona UAB, Univ Hosp Vall Hebron, Barcelona, Spain

[12] Koo Fdn, Sun Yat Sen Canc Ctr, Taipei, Taiwan

[13] Hosp Univ Son Espases, IdISBa Palma, Palma De Mallorca, Spain

[14] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[15] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[16] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[17] Lymphoma Diag & Treatment Ctr Henan Prov, Zhengzhou, Peoples R China

[18] Nantes Univ, Sch Med, Nantes, France

[19] Univ Hosp Nantes, Nantes, France

[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[21] Regeneron UK Ltd, Uxbridge, England

[22] Epworth Healthcare, Melbourne, Australia

[23] Univ Melbourne, Melbourne, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179818

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[1] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog
Kim, Tae Min
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle Limei
Prince, H. Miles
Oh, Sung Yong
Lim, Francesca
Carpio, Cecilia
Tran-Der Tan
Ayyappan, Sabarish
Gutierrez, Antonio
Li, Jingjin
Ufkin, Melanie
Zhu, Min
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Walewski, Jan
[J]. BLOOD, 2022, 140 : 1070 - 1071
[2] Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies
Zhu, Min
Conrado, Daniela
Srinivasan, Kamal
Brouwer-Visser, Jurriaan
Yan, Hong
Mohamed, Hesham
Chaudhry, Aafia
Ambati, Srikanth
Harnisch, Lutz
Davis, John D.
[J]. BLOOD, 2023, 142
[3] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Chong, Geoffrey
Taszner, Michal
Novelli, Silvana
Cho, Seok-Goo
Villasboas, Jose C.
Ubieto, Ana Jimenez
Tessoulin, Benoit
Poon, Michelle
Tucker, David
Walewski, Jan
Song, Yuqin
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu
Jagadeesh, Deepa
Luminari, Stefano
Mayer, Laura Magnano
Iskierka-Jazdzewska, Elzbieta
Tani, Monica
Cai, Jingxian
Uppala, Amulya
Shariff, Saleem
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Kim, Tae Min
[J]. CANCER RESEARCH, 2024, 84 (07)
[4] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[5] Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta
Kim, Won Seog
Cho, Seok-Goo
Kim, Tae Min
Jarque, Isidro
Robak, Tadeusz
Poon, Michelle
Prince, H. Miles
Yong, Sung
Lim, Francesca
Carpio, Cecilia
Tan, Tran-Der
Ayyappan, Sabarish
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ivanescu, Cristina
[J]. BLOOD, 2023, 142
[6] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
de Vos, S
Fernando, D
Schenkein, DP
Rosen, PJ
[J]. BLOOD, 2005, 106 (11) : 267B - 267B
[7] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
[J]. BLOOD, 2022, 140 : 7906 - 7907
[9] An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Borchmann, P.
Tam, C. S.
Jaeger, U.
McGuirk, J. P.
Holte, H.
Waller, E. K.
Jaglowski, S. M.
Bishop, M. R.
Andreadis, C.
Foley, S. R.
Westin, J. R.
Fleury, I.
Ho, P. J.
Mielke, S.
Salles, G.
Maziarz, R. T.
Anak, Oe
Pacaud, L. B.
del Corral, C.
Awasthi, R.
Agoulnik, S.
Tai, F.
Schuster, S. J.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 36 - 37
[10] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Witzig, Thomas E.
Maddocks, Kami J.
De Vos, Sven
Lyons, Roger M.
Edenfield, William Jeffery
Sharman, Jeff Porter
Vose, Julie
Yimer, Habte Aragaw
Wei, Helen
Chan, Edward M.
Patel, Priti
Di Simone, Christopher
Gandhi, Mitul
Vaughn, Jennifer
Kolibaba, Kathryn
Cheson, Bruce D.
Samaniego, Felipe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →